AMP as a Better Delivery System of Adenosine
Information source: Vanderbilt University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ischemia
Intervention: Adenosine (Drug); Adenosine Mono Phosphate (AMP) (Drug)
Sponsored by: Vanderbilt University
Official(s) and/or principal investigator(s):
Italo Biaggioni, M.D., Principal Investigator, Affiliation: Vanderbilt University
Adenosine and AMP are substances normally present in the body. Adenosine is also given for
the treatment of some heart rhythm problems and may be used to reduce heart damage during
heart attacks. The problem in using adenosine is that it is taken up by cells and,
therefore, very little of the adenosine we give by vein or in the artery actually reaches the
tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by
itself, but is converted to adenosine in tissue. We hope that by giving AMP we will increase
levels of adenosine in tissue. To see if this is true, we will give either adenosine or AMP
into the forearm artery while we measure how much adenosine reaches the forearm tissue.
Official title: Use of AMP to Improve Tissue Delivery of Adenosine
Study design: Other, Non-Randomized, Single Blind (Subject), Active Control, Crossover Assignment, Efficacy Study
Interstitial adenosine levels
Forearm blood flow
Minimum age: 18 Years.
Maximum age: 65 Years.
- Healthy volunteers
- Age 18-65
- Non smokers
- Any chronic disease
Locations and Contacts
Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States
Starting date: October 2003
Ending date: January 2008
Last updated: December 22, 2007